<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8385">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02108704</url>
  </required_header>
  <id_info>
    <org_study_id>HPPD</org_study_id>
    <nct_id>NCT02108704</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication Study in Parkinson's Disease</brief_title>
  <official_title>Helicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <authority>Malaysia: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been hypothesized, based on epidemiological observations, that Helicobacter pylori
      (HP) infection may play a role in the pathogenesis of Parkinson's Disease (PD). Previous
      studies have also shown that HP eradication therapy may result in improvements in levodopa
      pharmacokinetics and motor fluctuations. This study aims to examine the effects of HP
      eradication, using a double-blind randomized placebo-controlled trial design in a relatively
      large cohort of patients. Outcomes of interest include motor function, gastrointestinal
      symptoms and health-related quality of life. The investigators hypothesize that HP
      eradication will lead to improvements in motor function. The primary outcome of interest is
      the &quot;ON&quot;-medication Unified PD Rating Scale (UPDRS) Part III score at 3 months. Secondary
      outcomes include Purdue Pegboard Score, Timed Test of Gait, Dyskinesia and Bradykinesia
      scores measured by Parkinson's Kinetigraph (PKG), 72 hour Diary, Leeds Dyspepsia
      Questionnaire (LDQ), Parkinson's Disease Questionnaire (PDQ-39), UPDRS Part I, Part II and
      Part IV; and Montreal Cognitive Assessment (MOCA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>&quot;On-medication&quot; UPDRS Part III score</measure>
    <time_frame>at 3 months after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Kinetigraph (PKG) Bradykinesia and Dyskinesia Scores</measure>
    <time_frame>at 3 months post randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>72 hour motor diary</measure>
    <time_frame>at 3 months post randomisation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of Off time Time for medication to take effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leeds Dyspepsia Questionnaire</measure>
    <time_frame>at 3 months post randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson Disease Questionnaire (PDQ-39)</measure>
    <time_frame>at 3 months post randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Purdue Pegboard Score</measure>
    <time_frame>at 3 months after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Test of Gait</measure>
    <time_frame>at 3 months after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part I</measure>
    <time_frame>at 3 months after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part II</measure>
    <time_frame>at 3 months post randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part IV</measure>
    <time_frame>at 3 months post randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment Score</measure>
    <time_frame>at 3 months post randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Helicobacter pylori eradication therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Helicobacter pylori eradication therapy</intervention_name>
    <arm_group_label>Helicobacter pylori eradication therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged â‰¥18 years

          2. Provision of written informed consent

          3. Clinical diagnosis of Parkinson's Disease (PD) assigned by a consultant neurologist

        Exclusion Criteria:

          1. History of previous gastric or major abdominal/pelvic surgery

          2. History of previous eradication therapy for Helicobacter pylori

          3. Antibiotic use in the preceding four weeks or use of anti-acid/prokinetics/laxatives
             in the preceding one week prior to breath test

          4. Recent initiation of dopaminergic medications (within the last three months) or
             recent adjustment of dopaminergic medications (within the last one month)

          5. History of functional neurosurgery for PD

          6. No concomitant neurologic disease except PD

          7. Medical condition that prevents reliable completion of questionnaire
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ai Huey Tan, MD(UKM), MRCP(UK)</last_name>
    <email>aihuey.tan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai Huey Tan, MD(UKM), MRCP(UK)</last_name>
      <email>aihuey.tan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Helicobacter pylori infection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
